Flotation

Stealth Bio shifts to $78m IPO
Nan Fung-backed mitochondrial therapy developer Stealth BioTherapeutics floated at the foot of its range to raise $78m, having disclosed $100m in financing last June.
Harpoon snags public markets listing
The Taiho and Eli Lilly-backed immunotherapy developer floated in the middle of its range to raise $75.6m, valuing it at about $334m.
Stealth to make stock market appearance
Nan Fung-backed biopharmaceutical company Stealth Bio has filed for an IPO that could bring in almost $87m if it floats at the top of the range.
Alector achieves $176m IPO
The AbbVie, Eli Lilly, Amgen, Merck & Co and Alphabet-backed neurodegenerative disease drug developer is floating in the middle of its range.
IPO of the Year: DocuSign
A leading company in the e-signature and digital transaction management space, San Francisco-based DocuSign went public in April last year, with a market capitalization of $4.4bn.
Maoyan gets $250m for IPO ticket
Maoyan is floating in Hong Kong at the bottom of its range, in an offering that will provide exits to Enlight, Tencent and Meituan Dianping.
Alzheon withdraws second IPO attempt
Aptus-backed neurodegenerative-focused company Alzheon has withdrawn its second attempt at initial public offering, less than year after cancelling its first bid.
Venturing in 2018 – the trends
Rob Lavine, News editor for Global Corporate Venturing, reviews the trends in venturing from 2018

Other News

Analysis: Lyft to go public in 2019
The first flotation of a ride hailing business, expected in early 2019, will give an exit to a range of corporate investors and will move this business model into public markets.
Moderna loads up $604m in IPO
AstraZeneca, Merck & Co and Alexion all scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
Mogu modulates US IPO
Tencent, Ping An and Bertelsmann-backed e-commerce platform Mogu has floated on the New York Stock Exchange in a $66.5m initial public offering.
Moderna adjusts IPO target to $521m
AstraZeneca, Merck and Alexion-backed Moderna Therapeutics has set its pricing range at $22 to $24 and would raise more than $521m if it floats at the top end.
Tuanche settles on $20m IPO
The Bertelsmann automotive e-commerce platform has priced its shares at the lower end of its range to raise $20m instead of its targeted $150m.
Babytree nurses $217m IPO
Alibaba-backed Babytree priced its shares at the foot of its range and will raise $217m at a valuation of $1.5bn, down from $2.2bn earlier this year.

Editor's Picks

IPO of the Year: DocuSign
A leading company in the e-signature and digital transaction management space, San Francisco-based DocuSign went public in April last year, with a market capitalization of $4.4bn.
Orchard IPO bears $200m of fruit
GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
Innovent enters public markets with $421m IPO
Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.
Allogene rallies to $324m IPO
The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.
test reg

Login